Yingying Lu

Yingying Lu

Auto-generated profile, based on publicly available information

Yingying Lu

Department of Critical Care Medicine, Nanjing Jinling Hospital, Medical School of Southeast University, Nanjing 210002, China; Medical School of Southeast University, Nanjing 210002, China

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2023 in International Immunopharmacology
Verified
Journal Article
Open access
YLYingying Lu
Yingying Lu
BLBaiqiang Li
Baiqiang Li
MWMei Wei
Mei Wei
QZQingtian Zhu
Qingtian Zhu
LGLin Gao
Lin Gao
WLWeiqin Li
Weiqin Li
Recent clinical studies have shown that serum high-density lipoprotein (HDL) levels are correlated with acute pancreatitis (AP) severity. We aimed to investigate the role of HDL in pancreatic necrosis in AP. ApoA-I is the main constitution and function component of HDL. The roles of healthy human-derived HDL and apoA-I mimic peptide D4F were demonstrated in AP models in vivo and in vitro. Constitutive Apoa1 genetic inhibition on AP severity, especially pancreatic necrosis was assessed in both caerulein and sodium taurocholate induced mouse AP models. In addition, constitutive (Casp1-/-) and acinar cell conditional (Pdx1CreNlrp3Δ/Δ and Pdx1CreGsdmdΔ/Δ) mice were used to explore the effects of HDL on acinar cell pyroptosis in AP. Apoa1 knockout dramatically aggravated pancreatic necrosis. Human-derived HDL protected against acinar cell death in vivo and in vitro. We found that mimic peptide D4F also protected against AP very well. Constitutive Casp1 or acinar cell-conditional Nlrp3 and Gsdmd genetic inhibition could counteract the protective effects of HDL, implying HDL may exert beneficial effects on AP through inhibiting acinar cell pyroptosis. This work demonstrates the protective role of HDL and apoA-I in AP pathology, potentially driven by the inhibition of NLRP3 inflammasome signaling and acinar cell pyroptosis. Mimic peptides have promise as specific therapies for AP.

12 July 2017 in Oncology Letters
Verified
Journal Article
Open access
PDF file
XWXuebo Wang
Xuebo Wang
XYXiumei Yu
Xiumei Yu
QWQingli Wang
Qingli Wang
YLYingying Lu
Yingying Lu
HCHaixia Chen
Haixia Chen
This study investigated the expression of special AT‑rich sequence‑binding protein 1 (SATB1) and toll‑like receptor 4 (TLR4) protein in breast cancer and its clinical significance. We collected breast cancer tissues from 120 patients and adjacent non‑cancerous tissue from 53 patients. SATB1 was expressed in 89 cases of breast cancer (74.17%) and in 7 cases of adjacent non‑cancerous tissue (13.21%). TLR4 was expressed in 70 cases of breast cancer tissues (58.33%) and in 48 cases of adjacent non‑cancerous tissue (90.57%). The differences of SATB and TLR4 in breast cancer and adjacent non‑cancerous tissue were statistically significant. We found a negative correlation between the expression of SATB1 and TLR4 (r=‑0.624, P<0.05). The expression of SATB1 and TLR4 were not significantly correlated with age, menopause, and PR and HER‑2 protein expression, but were significantly correlated with tumor size, local lymphatic metastasis, histopathological grade, tumor stage, and ER protein expression (P<0.05). Overall, SATB1 and TLR4 proteins are involved in the development of breast cancer, a finding of great significance to identify therapeutic targets and prognosis markers for breast cancer.

1 January 2008 in World Journal of Gastroenterology
Verified
Journal Article
Open access
YLYing-Ying Lu
Ying-Ying Lu
DJDa-Dao Jing
Da-Dao Jing
MXMing Xu
Ming Xu
KWKai Wu
Kai Wu
XWXingpeng Wang
Xingpeng Wang
AIM: To investigate the effect and mechanism of action of erlotinib, an epidermal growth factor receptor (EGFR) small molecule tyrosine kinase inhibitor (TKI), in the human pancreatic cancer cell line BxPC-3 both in vitro and in vivo. METHODS: In vitro, human pancreatic cancer cell line BxPC-3 was exposed to varying concentrations of erlotinib, and its effects on proliferation, cell cycle distribution, apoptosis and the expression of pro- and antiapoptotic factors such as bcl-2, bcl-xl, bax and bak, and the expression of vascular endothelial cell growth factor (VEGF) were measured with 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, flow cytometric analysis, terminal deoxynucleotidyl transferase-mediated nick end labeling assay (TUNEL), and reverse transcription-polymerase chain reaction (RT-PCR). Potential effect of erlotinib on angiogenesis was examined by tube formation assay. Tumor growth suppression was observed in xenografted nude mice with pancreatic cancer in vivo. Immunohistochemical (IHC) staining for EGFR and factor VIII-related antigen was undertaken to detect the microvessel density and VEGF expression in tumor tissue in xenograft nude mice. RESULTS: Erlotinib, as a single agent, repressed BxPC-3 cell growth in a dose-dependent manner, triggered G1 arrest and induced cell apoptosis, and suppressed capillary formation of endothelium in vitro. Expressions of VEGF were significantly down-regulated at a high concentration of 200 μmol/L, however, the expressions of bcl-2 and bcl-xl were decreased at 50 μmol/L. In vivo, Erlotinib-treated mice demon-strated a reduced tumor volume, weight and microvessel density as compared to the control. IHC staining showed decreased expression of EGFR and RT-PCR had lower VEGF expression in treated mice. CONCLUSION: The in vitro and in vivo findings provide evidence that BxPC-3 cells are inhibited with erlotinib treatment. Inhibition of EGFR may be a promising adjuvant chemotherapy strategy in pancreatic cancer treatment.

1 January 2021 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
YLYingying Lu
Yingying Lu
GLGuotao Lu
Guotao Lu
LGLin Gao
Lin Gao
QZQingtian Zhu
Qingtian Zhu
JXJing Xue
Jing Xue
ZTzhihui tong
zhihui tong
Background and Purpose. Previous studies showed that Maresin1 (MaR1), one of the metabolites from docosahexaenoic acid (DHA), could alleviate acute inflammation and prompt inflammation resolution. Also, it attenuated pancreatic injury in caerulein‐induced acute pancreatitis (AP) in mice. However, the mechanisms underlying this suppression of inflammation and AP remain unknown. Method. Repeated caerulein injection was used to induce AP and chronic pancreatitis (CP) models in mice. The histopathological and serological changes were examined for evaluating the severity of the AP model, and flow cytometry was used for detecting macrophage phagocytosis and phenotype. Meanwhile, clodronate liposomes were used for macrophage depletion in mice. Finally, the CP model was adopted to further observe the protective effect of MaR1. Result. MaR1 administration manifested the improved histopathological changes and the lower serum levels of amylase and lipase. However, MaR1 played no protective role in the pancreatic acinar cell line in vitro. It obviously reduced the macrophage infiltration in the injured pancreas, especially M1‐type macrophages. After macrophage clearance, MaR1 showed no further protection in vivo. This study also demonstrated that MaR1 could alleviate fibrosis to limit AP progression in the CP model. Conclusion. Our data suggests that MaR1 was a therapeutic and preventive target for AP in mice, likely operating through its effects on decreased macrophage infiltration and phenotype switch.

3 May 2024 in The American Journal of Pathology
Verified
Journal Article
Closed access
XXXiaochun Xie
Xiaochun Xie
YLYang Liu
Yang Liu
QYQi Yang
Qi Yang
XMXiaojie Ma
Xiaojie Ma
YLYingying Lu
Yingying Lu
WLWeiqin Li
Weiqin Li

1 August 2020 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
DJDadao Jing
Dadao Jing
JJJie Jin
Jie Jin
ZMZhu Mei
Zhu Mei
QZQingqing Zhu
Qingqing Zhu
YLYingying Lu
Yingying Lu
XWXingpeng Wang
Xingpeng Wang
Background: Human inter-α-trypsin inhibitor heavy chain 4 (ITIH4) is an acute phase response protein that is positively regulated by interleukin-6 (IL-6), suggesting that ITIH4 can be used as an early serological biomarker of gastric cancer. Methods: The mechanism of ITIH4 elevation in gastric cancer cells was investigated via Helicobacter pylori (H. pylori) with or without recombinant human interleukin-6 (rhIL-6) in human gastric cell line AGS cells. The messenger RNA (mRNA) expressions of ITIH4 and IL-6 in AGS cells were detected with real-time quantitative polymerase chain reaction (qPCR), while the expression of ITIH4 protein and IL-6 in AGS cells was detected with Western blot and enzyme-linked immunosorbent assay (ELISA) methods. Results: We found that the mRNA and protein expressions of ITIH4 started to increase synchronously at 3 hours (h), peaked at 12 h, and then declined to normal a level at 24 h in AGS cells after H. pylori infection. Interestingly, the expression patterns of ITIH4 were positively correlated to IL-6 expression levels. In the ITIH4 expression experiment with IL-6 administration, the expression level of ITIH4 began to increase at a concentration of 6.25 ng/mL with rhIL-6 administration, reach a peak, and plateau at a concentration of 25 ng/mL of rhIL-6. The expression patterns of ITIH4 in AGS cells induced by H. pylori infection were closely related to the infection of H. pylori and the level of IL-6. Conclusions: The detection of ITIH4 and IL-6 during H. pylori infection may be useful for the screening of early gastric cancer.